No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical firm focused on the research, creation, and marketing of diverse pharmaceutical products. Operating within the People's Republic of China, its therapeutic focus spans oncology, metabolic disorders, autoimmune conditions, neurological ailments, and infectious diseases. Among its offerings is JS001, marketed as TUOYI, a recombinant humanized anti-PD-1 monoclonal antibody. This treatment is prescribed for a wide array of cancers, including melanoma (both cutaneous and mucosal), soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. The company's development pipeline also includes UBP1211, a biosimilar version of Humira, intended for rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Additionally, they are advancing JS002, a recombinant humanized anti-PCSK9 monoclonal antibody designed to address hyperlipidemia, and UBP1213, an injectable recombinant humanized anti-BLyS monoclonal antibody. Further projects encompass JS501, a biosimilar of Avastin; JS003, an injectable recombinant humanized anti-PD-L1 monoclonal antibody; JS101, which acts as a pan-CDK inhibitor; TAB004/JS004, an injectable recombinant humanized anti-BTLA monoclonal antibody; and JS005, another injectable recombinant humanized anti-IL-17A monoclonal antibody. Furthermore, Junshi Biosciences holds partnerships, including an agreement with Eli Lilly and Company to collaboratively develop therapeutic antibodies aimed at the prevention and treatment of COVID-19, the illness resulting from the SARS-CoV-2 novel coronavirus. Another collaboration is with Coherus Biosciences, Inc. for the advancement and commercialization of toripalimab, which is Junshi Biosciences' anti-PD-1 antibody. Established in 2012, Shanghai Junshi Biosciences Co., Ltd. maintains its primary offices in Shanghai, People's Republic of China.
www.junshipharma.comNo one on the platform currently holds 1877.HK.
No tracked institution reports a position in 1877.HK as of their last filing.
No one on the platform has traded 1877.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 24.9% | 8.8% | ||||
| Profit Margin % | -35.0% | -86.9% | -10881.9% | |||
| Free Cash Flow Margin % | -49.9% | -107.1% | -18486.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $3.6B | +40.8% | $-0.23 | $-0.25–$-0.22 | — | 2 |
| 2027 | $4.4B | +22.8% | $0.11 | $0.11–$0.12 | — | 2 |
| 2028 | $5.4B | +23.7% | $0.37 | $0.27–$0.47 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 1877.HKShanghai Junshi Biosciences Co., Ltd. | $17.28 | +0.12% | $24.3B | — |
| 0874.HKGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited | $13.20 | -0.68% | $32.8B | — |
| 1548.HKGenscript Biotech Corporation | $32.38 | -4.76% | $70.7B | — |
| 1952.HKEverest Medicines Limited | $26.28 | -3.10% | $9.2B | — |
| 2096.HKSimcere Pharmaceutical Group Limited | $11.25 | -1.23% | $28.9B | — |
| 2696.HKShanghai Henlius Biotech, Inc. | $59.25 | -8.21% | $32.2B | — |
| 6821.HKAsymchem Laboratories (Tianjin) Co., Ltd. | $156.40 | +2.02% | $56.4B | — |
Source: Financial Modeling Prep · peers by sector/industry